• Futuna Blue España SL

  Participated · Equity · Jun 2018

  Futuna develops technology for the breeding of alevines (fish larvae) of high‑value species and has broad experience in grow‑out using Recirculating Aquaculture Systems (RAS). The company is specialized in the aquaculture sector and serves agriculture/fisheries markets. After the reported financing, Futuna aims to diversify its activity and scale to become one of the principal producers of alevines of new species worldwide. The article cites the company’s operational expertise in RAS as a core competency. The company is based in Puerto de Santa María (Cádiz). In May 2018 Futuna completed a fundraising round that supports its expansion plans. No operating metrics (revenue or user numbers) were disclosed in the article.

• nLife Therapeutics

  Participated · Equity · Jun 2014

  nLife Therapeutics is a nanomedicine biotechnology company based in Armilla (Granada) focused on developing therapeutic agents for disorders of the central nervous system. The company said it will use newly awarded funds to carry out research on CNS therapeutic agents. In September 2014 it received a $350,000 grant from the Michael J. Fox Foundation (about €273,000). Earlier, the company closed a €2 million financing round in June led by Healthequity. Caixa Capital Risc and Invercaria also participated in that round; those two VCs had previously invested €5 million in February 2012. Crossroad Biotech is also an investor in the company. nLife Therapeutics is a biotechnology company based in Granada, Spain, that develops oligonucleotides as therapeutic agents for CNS disorders. Led by CEO Andrés Montefeltro, the company's pipeline includes programs targeting Parkinson disease (NLF-PD), morbid obesity (NLF-MO), and major depressive disorder (NLF-MDD). The company closed a €2m funding round to advance its therapeutics, particularly to support development of its Parkinson disease program. Backers in the round include Caixa Capital Risc, Healthequity, and Invercaria. The funds will be used to progress its CNS-focused programs toward further development. nLife Therapeutics is a Granada, Spain–based company developing next-generation targeted nucleic acid treatments for central nervous system diseases. Its technology delivers conjugated nucleic acids linked to small chemicals to selected neurons after a single intranasal application. The company has launched siRNA-based programs targeting Parkinson's disease, morbid obesity and major depressive disorder. nLife raised €5m in funding and intends to use the proceeds to advance clinical trials for its treatments. Backers include la Caixa (through Caixa Capital Risc and Caixa Capital Biomed) and Invercaria (through the Jeremie fund), each investing €2.5m.

• Ingeniatrics

  Participated · Equity · Feb 2011

  Ingeniatrics develops micro- and nanoscale production technologies (Flow Focusing® and Flow Blurring) to design and produce microparticles of chosen size, structure and composition. The company holds over 50 patents and patent applications related to these technologies. Its Flow Focusing® microencapsulation method was invented and developed by the company’s president, Alfonso Miguel Gañán Calvo. Founded in 2001 by biotech entrepreneurs and researchers from the University of Seville, Ingeniatrics is based in Seville and currently employs 20 people. The company raised €1.6M in funding and intends to use the proceeds to build an industrial-scale production plant for microencapsulation. It also plans to recruit international marketing managers and obtain necessary certifications to commercialize its technologies.

No current team members are available.